Results 31 to 40 of about 5,338,748 (296)

Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies

open access: yesFrontiers in Cell and Developmental Biology, 2023
Introduction: The glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab has been licensed for treatment in follicular non-Hodgkin lymphoma and B-CLL following clinical trials demonstrating superior outcomes to standard of care treatment ...
Ester Fagnano   +10 more
doaj   +1 more source

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

open access: yesOncoImmunology, 2023
Despite breakthroughs in immune checkpoint inhibitors (ICI), the majority of tumors, including those poorly infiltrated by CD8+ T cells or heavily infiltrated by immunosuppressive immune effector cells, are unlikely to result in clinically meaningful ...
Debayan Mukherjee   +14 more
doaj   +1 more source

Aptamers and antibodies: rivals or allies in cancer targeted therapy?

open access: yes, 2021
The goal of an efficacious cancer therapy is to specifically target diseased cells at high accuracy while sparing normal, healthy cells. Over the past three decades, immunotherapy, based on the use of monoclonal antibodies (mAbs) directed against tumor ...
Camorani, Simona   +3 more
core   +1 more source

Recist and targeted therapy [PDF]

open access: yesActa Radiologica, 2009
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract.
openaire   +2 more sources

Targeted Therapies in Melanoma [PDF]

open access: yesSurgical Oncology Clinics of North America, 2015
Advances in understanding the biology of melanoma have provided great insights about the mechanisms of chemoresistance and its genetic heterogeneity in parallel with advances in drug design culminating in recent major treatment breakthroughs using small molecules inhibitors in metastatic melanoma (MM).
Stergios J, Moschos, Ramya, Pinnamaneni
openaire   +2 more sources

Targeted therapies for cancer

open access: yesBMC Medicine, 2022
Abstract Targeted therapy is the key for improving overall survival while decreasing the undesirable adverse effects of cancer treatment. Patients who received matched targeted therapies showed dramatically improved overall survival (OS) and progression-free survival (PFS) compared to those without matched ...
Zhijun Zhou, Min Li
openaire   +3 more sources

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy

open access: yesNature Communications
The combination of radiotherapy/chemoradiotherapy and immune checkpoint blockade can result in poor outcomes in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
Emmanuel C. Patin   +23 more
doaj   +1 more source

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors

open access: yesMolecular Therapy: Oncolytics, 2021
Prostate cancers are considered “cold” tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells.
Nicola E. Annels   +8 more
doaj   +1 more source

Early Body Mass Index z‐Score Change and Resolution of Severe Malnutrition in Children With Sickle Cell Anemia in a Low‐Income Setting: A Prospective Single‐Arm Extension Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Children with sickle cell anemia (SCA) in low‐income settings are at risk of severe malnutrition, but optimal nutritional management has not been established. We evaluated an intensified ready‐to‐use therapeutic food (RUTF) regimen in children with persistent severe malnutrition after initial treatment and assessed whether early ...
Safiya Gambo   +9 more
wiley   +1 more source

Central Nervous System Tumors Among Infants in Canada: A Report From CYP‐C

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) tumors in infants are rare, pose unique clinical challenges, and lack large‐scale evidence‐based data to guide management. This study seeks to describe CNS tumors in Canadian infants and to compare their outcomes with those of older children.
Samuel Sassine   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy